ProCE Banner Activity

CME

Progress in Acute Myeloid Leukemia: Adapting Treatment to Individual Patients

Multimedia
Watch this on-demand Webcast from the CCO AML satellite symposium at ASH 2017, featuring expert faculty Jeffrey E. Lancet, MD; Gail J. Roboz, MD; B. Douglas Smith, MD; and Roland B. Walter, MD, PhD, MS, as they discuss the most clinically relevant advances in treatment strategies for patients with AML.

Physicians : maximum of 3.25 AMA PRA Category 1 {Credits}

Released: January 31, 2018

Expiration: January 30, 2019

No longer available for credit.

Share

Faculty

Jeffrey E. Lancet

Jeffrey E. Lancet, MD

Senior Member & Professor
Chair,
 Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Gail J. Roboz

Gail J. Roboz, MD

Associate Director of the Leukemia Program
Assistant Professor of Medicine
Weill Medical College
Cornell University

Roland B. Walter

Roland B. Walter, MD, PhD, MS

Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Associate Professor of Medicine
Division of Hematology
Department of Medicine
University of Washington School of Medicine
Adjunct Associate Professor 
Departments of Pathology and Epidemiology
University of Washington School of Public Health
Seattle, Washington

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by educational grants from

Astellas Text

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals Inc

Pfizer, Inc.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify prognostic or therapeutically relevant molecular (genetic, epigenetic, protein) features or aberrations in AML and describe their clinical importance in terms of risk prediction, diagnosis, and prognosis
  • Summarize current evidence on the benefits of standard chemotherapy-based protocols and emerging therapies for the treatment of AML, including in elderly patients, those with relapsed/refractory disease, or patients with poor-risk cytogenetics
  • Discuss emerging safety and efficacy data and ongoing clinical trials evaluating next-generation cytotoxics, epigenetic treatments, immunotherapies, and targeted agents for patients with AML who may not benefit from standard therapy
  • Discuss promising investigational treatments with patients with AML who may benefit from enrollment on clinical trials evaluating next-generation targeted agents, cytotoxics, epigenetic treatments, and immunotherapies

Program Director Disclosure

Program Director

Jeffrey E. Lancet, MD

Senior Member & Professor
Chair,
 Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Jeffrey E. Lancet, MD, has disclosed that he has received consulting fees from Bio-Path Holdings, BioSight, Celgene, Erytech, and Janssen and funds for research support from BioSight and Celgene.

Faculty Disclosure

Primary Author

Gail J. Roboz, MD

Associate Director of the Leukemia Program
Assistant Professor of Medicine
Weill Medical College
Cornell University

Gail J. Roboz, MD, has disclosed that she has received consulting fees from AbbVie, Amgen, Amphivena Therapeutics, Array BioPharma, Astex, Celgene, Celltrion, Genoptix, Janssen, MedImmune, Novartis, Pfizer, Sandoz, and Sunesis and funds for research support from Cellectis.

Roland B. Walter, MD, PhD, MS

Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Associate Professor of Medicine
Division of Hematology
Department of Medicine
University of Washington School of Medicine
Adjunct Associate Professor 
Departments of Pathology and Epidemiology
University of Washington School of Public Health
Seattle, Washington

Roland B. Walter, MD, PhD, MS, has disclosed that he has received consulting fees from Agios, Amphivena, Aptevo, BioLineRx, Covagen, Jazz, and Race Oncology; funds for research support from AbbVie, ADC Therapeutics, Amgen, Arog, Celator/Jazz, Covagen, Pharmacyclics, Seattle Genetics, and Stemline Therapeutics; and holds ownership interests with Amphivena.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Creditsâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 3.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 31, 2018, through January 30, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to help participants align their clinical practice with practice-changing findings and current guidelines for the treatment of acute myeloid leukemia.